The effect of metformin on sirtuin gene expression in obese children and adolescents

Investigation of metformin effect on sirtuin gene expression in peripheral blood mononuclear cells with obesity and metabolic syndrome in children and adolescents of 8-18 years old

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201104164585N4

Enrollment

Registered

2016-06-18

Start date

2016-05-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity. Obesity due to excess calories

Interventions

Intervention 1: Metformin 1000 mg/m2 body surface as tablet, daily for 12 weeks, oral. Intervention 2: placebo one tablet daily for 12 weeks, oral.

Treatment - Drugs

Placebo

Metformin 1000 mg/m2 body surface as tablet, daily for 12 weeks, oral

placebo one tablet daily for 12 weeks, oral

Eligibility

Sex/Gender

All

Age

8 Years to 16 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: obese subjects (BMI>95th percentile); not having any specific ilnesses; not taking medications including antihypertensive drugs or those interfering lipid or carbohydrate metabolism Exclusion criteria: having any endocrine disease other than obesity or diseases such as gastrointestinal, renal, cardiovascular, etc. ; taking any mediacation; BMI less than 5th percentile or between 85th and 95th percentiles

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sirt1 gene expression. Timepoint: 90 days. Method of measurement: real-time PCR.;AMPK. Timepoint: 90 days. Method of measurement: ELISA.	—

Secondary

Measure	Time frame
Insulin resistance. Timepoint: 90 days. Method of measurement: HOMA-IR calculated from insulin and glucose levels.;Blood glucose. Timepoint: 90 days. Method of measurement: colorimetric.;Waist circumference. Timepoint: 90 days. Method of measurement: measuring tape.;Blood pressure. Timepoint: 90 days. Method of measurement: sphygmomanometer.;Weight. Timepoint: 90 days. Method of measurement: scale.;Cholesterol. Timepoint: 90 days. Method of measurement: colorimetric.;LDL. Timepoint: 90 days. Method of measurement: colorimetric.;HDL. Timepoint: 90 days. Method of measurement: colorimetric.;Triglyceride. Timepoint: 90 days. Method of measurement: colorimetric.;BMI. Timepoint: 90 days. Method of measurement: calculation from weight and height.;Insulin. Timepoint: 90 days. Method of measurement: ELISA.	—

Measure

Time frame

Insulin resistance. Timepoint: 90 days. Method of measurement: HOMA-IR calculated from insulin and glucose levels.;Blood glucose. Timepoint: 90 days. Method of measurement: colorimetric.;Waist circumference. Timepoint: 90 days. Method of measurement: measuring tape.;Blood pressure. Timepoint: 90 days. Method of measurement: sphygmomanometer.;Weight. Timepoint: 90 days. Method of measurement: scale.;Cholesterol. Timepoint: 90 days. Method of measurement: colorimetric.;LDL. Timepoint: 90 days. Method of measurement: colorimetric.;HDL. Timepoint: 90 days. Method of measurement: colorimetric.;Triglyceride. Timepoint: 90 days. Method of measurement: colorimetric.;BMI. Timepoint: 90 days. Method of measurement: calculation from weight and height.;Insulin. Timepoint: 90 days. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDavod Amirkashani

H. Aliasghar Hospital, Iran University of Medical Sciences

amirkashani58@yahoo.com+98 913 163 5097

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026